Longitudinal preclinical evaluation of the novel radioligand [11C]CHDI-626 for PET imaging of mutant huntingtin aggregates in Huntington's disease.

Daniele BertoglioJeroen VerhaegheAlan MirandaLeonie WyffelsSigrid StroobantsLadislav MrzljakVinod KhetarpalMette SkinbjergLongbin LiuCelia DominguezIgnacio Munoz-SanjuanJonathan BardSteven Staelens

Published in: European journal of nuclear medicine and molecular imaging (2021)

With clinical evaluation underway, [11C]CHDI-626 PET imaging appears to be a suitable preclinical candidate marker to monitor natural HD progression and for the evaluation of mHTT-lowering therapies.

Keyphrases

pet imaging
clinical evaluation
cell therapy
positron emission tomography
cross sectional
stem cells